Roy Taylor (diabetologist): Difference between revisions
Content deleted Content added
Reverted to revision 934964451 by Winged Blades of Godric (talk): Rv to last good (Twinkle) |
add |
||
| Line 1: | Line 1: | ||
Roy Taylor is a physician and diabetologist from [[Newcastle University]], UK. Scopus h-index is 47. |
Roy Taylor is a physician and diabetologist from [[Newcastle University]], UK. Scopus h-index is 47.{{Cite web|url=https://www.scopus.com/authid/detail.uri?authorId=7405756928|title=Scopus preview - Scopus - Author details (Taylor, Roy W.)|website=www.scopus.com|access-date=2020-01-09}} |
||
== Publications == |
|||
*{{Cite journal|last=Belch|first=Jill|last2=MacCuish|first2=Angus|last3=Campbell|first3=Iain|last4=Cobbe|first4=Stuart|last5=Taylor|first5=Roy|last6=Prescott|first6=Robin|last7=Lee|first7=Robert|last8=Bancroft|first8=Jean|last9=MacEwan|first9=Shirley|last10=Shepherd|first10=James|last11=Macfarlane|first11=Peter|date=2008-10-16|title=The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease|url=https://www.bmj.com/content/337/bmj.a1840|journal=BMJ|language=en|volume=337|doi=10.1136/bmj.a1840|issn=0959-8138|pmc=PMC2658865|pmid=18927173}} |
|||
*{{Cite journal|last=Lim|first=E. L.|last2=Hollingsworth|first2=K. G.|last3=Aribisala|first3=B. S.|last4=Chen|first4=M. J.|last5=Mathers|first5=J. C.|last6=Taylor|first6=R.|date=2011-10-01|title=Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol|url=https://doi.org/10.1007/s00125-011-2204-7|journal=Diabetologia|language=en|volume=54|issue=10|pages=2506–2514|doi=10.1007/s00125-011-2204-7|issn=1432-0428|pmc=PMC3168743|pmid=21656330}} |
|||
*{{Cite journal|last=Lean|first=Michael EJ|last2=Leslie|first2=Wilma S|last3=Barnes|first3=Alison C|last4=Brosnahan|first4=Naomi|last5=Thom|first5=George|last6=McCombie|first6=Louise|last7=Peters|first7=Carl|last8=Zhyzhneuskaya|first8=Sviatlana|last9=Al-Mrabeh|first9=Ahmad|last10=Hollingsworth|first10=Kieren G|last11=Rodrigues|first11=Angela M|date=2018-02-10|title=Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial|url=http://www.sciencedirect.com/science/article/pii/S0140673617331021|journal=The Lancet|volume=391|issue=10120|pages=541–551|doi=10.1016/S0140-6736(17)33102-1|issn=0140-6736}} |
|||
== References == |
== References == |
||
Revision as of 12:38, 10 January 2020
Roy Taylor is a physician and diabetologist from Newcastle University, UK. Scopus h-index is 47."Scopus preview - Scopus - Author details (Taylor, Roy W.)". www.scopus.com. Retrieved 2020-01-09.
Publications
- Belch, Jill; MacCuish, Angus; Campbell, Iain; Cobbe, Stuart; Taylor, Roy; Prescott, Robin; Lee, Robert; Bancroft, Jean; MacEwan, Shirley; Shepherd, James; Macfarlane, Peter (2008-10-16). "The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease". BMJ. 337. doi:10.1136/bmj.a1840. ISSN 0959-8138. PMC 2658865. PMID 18927173.
{{cite journal}}: CS1 maint: PMC format (link) - Lim, E. L.; Hollingsworth, K. G.; Aribisala, B. S.; Chen, M. J.; Mathers, J. C.; Taylor, R. (2011-10-01). "Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol". Diabetologia. 54 (10): 2506–2514. doi:10.1007/s00125-011-2204-7. ISSN 1432-0428. PMC 3168743. PMID 21656330.
{{cite journal}}: CS1 maint: PMC format (link) - Lean, Michael EJ; Leslie, Wilma S; Barnes, Alison C; Brosnahan, Naomi; Thom, George; McCombie, Louise; Peters, Carl; Zhyzhneuskaya, Sviatlana; Al-Mrabeh, Ahmad; Hollingsworth, Kieren G; Rodrigues, Angela M (2018-02-10). "Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial". The Lancet. 391 (10120): 541–551. doi:10.1016/S0140-6736(17)33102-1. ISSN 0140-6736.